Cevimeline

Pharmacogenomic Information in the Context of the FDA-Approved Drug Label*

Cevimeline is a muscarinic agonist which binds to muscarinic receptors. Cevimeline is indicated for the treatment of symptoms of dry mouth in patients with Sjögrens Syndrome. Cytochrome P450 enzymes CYP2D6 and CYP3A3/4 are responsible for the metabolism of cevimeline.
Excerpts from the Cevimeline drug label:

"Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. Cevimeline should be used with caution in individuals known or suspected to be deficient in CYP2D6 activity, based on previous experience, as they may be at a higher risk of adverse events."

(For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Cevimeline drug label PDF.)